NSE - Free Realtime Quote INR

Alkem Laboratories Limited (ALKEM.NS)

Compare
5,344.10
-31.95
(-0.59%)
As of 10:43:12 AM GMT+5:30. Market Open.
Loading Chart for ALKEM.NS
DELL
  • Previous Close 5,376.05
  • Open 5,301.00
  • Bid 5,340.40 x --
  • Ask 5,344.05 x --
  • Day's Range 5,274.60 - 5,382.45
  • 52 Week Range 4,407.05 - 6,439.90
  • Volume 18,255
  • Avg. Volume 266,478
  • Market Cap (intraday) 638.967B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 30.12
  • EPS (TTM) 177.41
  • Earnings Date Feb 7, 2025 - Feb 11, 2025
  • Forward Dividend & Yield 10.00 (0.18%)
  • Ex-Dividend Date Aug 9, 2024
  • 1y Target Est 5,777.67

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

www.alkemlabs.com

17,432

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ALKEM.NS

View More

Performance Overview: ALKEM.NS

Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

ALKEM.NS
4.04%
S&P BSE SENSEX
1.57%

1-Year Return

ALKEM.NS
6.65%
S&P BSE SENSEX
6.13%

3-Year Return

ALKEM.NS
48.60%
S&P BSE SENSEX
25.95%

5-Year Return

ALKEM.NS
148.03%
S&P BSE SENSEX
85.14%

Compare To: ALKEM.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ALKEM.NS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    642.79B

  • Enterprise Value

    610.17B

  • Trailing P/E

    30.29

  • Forward P/E

    25.64

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.15

  • Price/Book (mrq)

    5.59

  • Enterprise Value/Revenue

    4.89

  • Enterprise Value/EBITDA

    21.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.13%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    127.32B

  • Net Income Avi to Common (ttm)

    20.54B

  • Diluted EPS (ttm)

    177.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    42.7B

  • Total Debt/Equity (mrq)

    13.24%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ALKEM.NS

View More

People Also Watch